With GLP-1 microdoses, Noom targets lower-BMI group outside FDA obesity drug labels

The telehealth company Noom plans to target people with a body mass index well below the requirements for FDA-approved obesity shots, using a microdose GLP-1 offering. The strategy is becoming more common, as online health ...